吡格列酮对晚期动脉粥样硬化病变的不同作用。
Differential effects of pioglitazone on advanced atherosclerotic lesions.
作者信息
Thorp Edward, Tabas Ira
出版信息
Am J Pathol. 2009 Sep;175(3):1348. doi: 10.2353/ajpath.2009.090483. Epub 2009 Aug 6.
Abstract
This Correspondence relates to Atherosclerosis in LDLR-knockout Mice in Inhibited, but not Reversed, by the PPARy Ligand Pioglitazone (Am J Pathol 2009 174:2007–2014).
摘要
本通讯涉及PPARγ配体吡格列酮可抑制但不能逆转低密度脂蛋白受体基因敲除小鼠的动脉粥样硬化（《美国病理学杂志》2009年第174卷：2007 - 2014页）。
相似文献
1
Differential effects of pioglitazone on advanced atherosclerotic lesions.
Am J Pathol. 2009 Sep;175(3):1348. doi: 10.2353/ajpath.2009.090483. Epub 2009 Aug 6.
2
Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.
Am J Pathol. 2009 Jun;174(6):2007-14. doi: 10.2353/ajpath.2009.080611. Epub 2009 May 12.
3
Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice.
Atherosclerosis. 2007 May;192(1):85-91. doi: 10.1016/j.atherosclerosis.2006.06.025. Epub 2006 Aug 9.
4
Pioglitazone: more than just an insulin sensitizer.
Hepatology. 2009 May;49(5):1427-30. doi: 10.1002/hep.22983.
5
[Effect of pioglitazone, one of TZDs, on IGT-patients].
Nihon Rinsho. 2005 Feb;63 Suppl 2:462-70.
6
[Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice].
Nihon Rinsho. 2010 Feb;68(2):229-34.
7
Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
Circulation. 2007 Nov 6;116(19):2182-90. doi: 10.1161/CIRCULATIONAHA.107.698852. Epub 2007 Oct 22.
8
Chronic LPSF/GQ-02 treatment attenuates inflammation and atherosclerosis development in LDLr mice.
Eur J Pharmacol. 2016 Nov 15;791:622-631. doi: 10.1016/j.ejphar.2016.09.037. Epub 2016 Sep 29.
9
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
Expert Opin Pharmacother. 2007 Aug;8(12):1985-98. doi: 10.1517/14656566.8.12.1985.
10
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Curr Mol Pharmacol. 2012 Jun;5(2):272-81. doi: 10.2174/1874467211205020272.
引用本文的文献
1
The Role of Efferocytosis in Atherosclerosis.
Circulation. 2017 Jan 31;135(5):476-489. doi: 10.1161/CIRCULATIONAHA.116.025684.
2
Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging.
Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1933-9. doi: 10.1161/ATVBAHA.110.206342. Epub 2010 Aug 5.
本文引用的文献
1
Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.
Am J Pathol. 2009 Jun;174(6):2007-14. doi: 10.2353/ajpath.2009.080611. Epub 2009 May 12.
2
Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
Circulation. 2007 Nov 6;116(19):2182-90. doi: 10.1161/CIRCULATIONAHA.107.698852. Epub 2007 Oct 22.
3
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet. 2005 Oct 8;366(9493):1279-89. doi: 10.1016/S0140-6736(05)67528-9.
4
Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency.
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2255-64. doi: 10.1161/01.ATV.0000184783.04864.9f. Epub 2005 Sep 1.
5
Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
J Clin Invest. 2004 Dec;114(11):1564-76. doi: 10.1172/JCI18730.
Zotero 插件